BIOYF:OTO-BioSyent Inc. (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic | OTC Pink

Last Closing

USD 8.05

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Volume

200.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biosyent Inc is a life science company engaged in marketing of pharmaceutical products & manufacturing & marketing of non-chemical bio & health-friendly insecticides. It acquires or license products & commercializes technology to health & public safety.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 83.17B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 47.69B
HLN Haleon plc

N/A

USD 47.33B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.37B
CTLT Catalent Inc

N/A

USD 10.83B
ELAN Elanco Animal Health

N/A

USD 7.59B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 2.67B
BHC Bausch Health Companies Inc

N/A

USD 2.33B
CPHI China Pharma Holdings Inc

N/A

USD 3.04M
YCBD cbdMD Inc

N/A

USD 2.14M

ETFs Containing BIOYF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.66% 53% F 80% B-
Dividend Return 1.43% 43% F 35% F
Total Return 17.09% 53% F 78% C+
Trailing 12 Months  
Capital Gain 39.27% 76% C+ 91% A-
Dividend Return 2.23% 57% F 34% F
Total Return 41.50% 76% C+ 91% A-
Trailing 5 Years  
Capital Gain 81.31% 75% C 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.31% 75% C 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 16.41% N/A N/A 62% D
Dividend Return 16.81% N/A N/A 59% D-
Total Return 0.40% N/A N/A 11% F
Risk Return Profile  
Volatility (Standard Deviation) 32.70% N/A N/A 68% D+
Risk Adjusted Return 51.41% N/A N/A 86% B+
Market Capitalization 0.08B 25% F 27% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.